Literature DB >> 27519560

Incidence and Risk Factors of Elevated Intraocular Pressure Following Deep Anterior Lamellar Keratoplasty.

Olivia S Huang1, Jodhbir S Mehta2, Hla M Htoon3, Donald T Tan2, Tina T Wong4.   

Abstract

PURPOSE: To report the incidence and risk factors of elevated IOP following deep anterior lamellar keratoplasty (DALK).
DESIGN: A retrospective case series.
METHODS: A retrospective study investigating the 5-year incidence of raised IOP following DALK cases performed from 2004 to 2008 in a tertiary center. Patients with less than 6 months of follow-up were excluded. Elevated IOP was defined as IOP >21 mm Hg.
RESULTS: An episode of elevated IOP occurred in 36.1% of cases (44/122 cases), 11.4% (n = 5) occurring within the first week. The average duration of raised IOP was 48.9 (SD: 65.5) days. Causes included pupil block from air, swollen grafts, and corticosteroid response. Surgical intervention to lower IOP was required in 3 cases (6.8%). In multivariate analyses, the use of Olopatadine 0.1% or cyclosporine eye drops before DALK (OR = 14.51, 95% CI = 1.43-147.23) and use of topical prednisolone acetate 1% compared with dexamethasone 0.1% post DALK (OR = 4.79, 95% CI = 0.73-31.52) were associated with higher rates of elevated IOP post DALK. At 5 years post DALK, 3 of 71 cases (4.48%) developed de novo glaucomatous field defects, and 1 case with pre-existing glaucoma had progression of glaucomatous field defect.
CONCLUSIONS: DALK was associated with a significant incidence of transiently elevated IOP postoperatively, but had a low incidence of de novo glaucoma at 5 years in our study. Risk factors for raised IOP post DALK included the use of topical prednisolone acetate 1% compared with dexamethasone 0.1%, and the use of Olopatadine 0.1% or any concentration of cyclosporine eye drops prior to DALK.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27519560     DOI: 10.1016/j.ajo.2016.07.025

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Relationship between Postoperative Intraocular Pressure and Refractive Outcomes in Patients after Deep Anterior Lamellar Keratoplasty.

Authors:  Dayna Yong Wei Wei; Liang Shen; Ray Manotosh; Anna Tan Wee Tien; Charmaine Chai Hui-Chen
Journal:  J Curr Ophthalmol       Date:  2022-04-16

2.  Surgical management of glaucoma following different keratoplasty techniques.

Authors:  Ozum Oztutuncu; Cigdem Altan; Gulsah Gumus; Banu Solmaz; Berna Basarir; Nese Alagoz; Tekin Yasar
Journal:  Int Ophthalmol       Date:  2022-04-02       Impact factor: 2.029

3.  Elevated Cytokine Levels in Aqueous Humor Are Associated with Peripheral Anterior Synechiae after Penetrating Keratoplasty.

Authors:  Yuki Kusano; Takefumi Yamaguchi; Sota Nishisako; Takehiro Matsumura; Masaki Fukui; Kazunari Higa; Toshihiro Inoue; Jun Shimazaki
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

Review 4.  Current Perspectives on Corneal Transplantation.

Authors:  Siyin Liu; Yee Ling Wong; Andrew Walkden
Journal:  Clin Ophthalmol       Date:  2022-03-04

5.  Outcome of Lamellar Graft Patching for the Treatment of Noninfectious Corneal Perforations.

Authors:  Takanori Suzuki; Takefumi Yamaguchi; Daisuke Tomida; Masaki Fukui; Jun Shimazaki
Journal:  Cornea       Date:  2021-11-22       Impact factor: 3.152

6.  Early intraocular pressure changes following different keratoplasty techniques and association with cornea parameters and anterior chamber depth.

Authors:  Gulsah Gumus; Cigdem Altan; Yusuf Yildirim; Nilay Kandemir Beşek; Selim Genç; Ahmet Kirgiz; Gonul Karatas Durusoy; Alper Ağca
Journal:  Ther Adv Ophthalmol       Date:  2022-03-19

7.  Demographic and clinical profile, surgical outcome, and quality of life in patients who underwent bilateral lamellar corneal grafts.

Authors:  Sreelakshmi P Amar; Rajesh Sinha; Nidhi Kalra; Tushar Agarwal; Namrata Sharma; Jeewan S Titiyal
Journal:  Indian J Ophthalmol       Date:  2021-07       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.